Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
1. SMMT's partner reported positive HARMONi trial results for ivonescimab. 2. Overall survival rate showed significant improvement, HR of 0.78. 3. Consistent results across diverse global patient populations observed. 4. Safety profile of ivonescimab remains favorable with no new safety signals. 5. Potential broad therapeutic benefits for cancer patients worldwide confirmed.